Skip to main content

Use of Antimicrobial Peptides Against Microbial Biofilms: Advantages and Limits

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

The formation of surface-attached cellular agglomerates, the so-called biofilms, contributes significantly to bacterial resistance to antibiotics and innate host defenses. Bacterial biofilms are associated to various pathological conditions in humans such as cystic fibrosis, colonization of indwelling medical devices and dental plaque formation involved in caries and periodontitis. Over the last years, natural antimicrobial peptides (AMPs) have attracted considerable interest as a new class of antimicrobial drugs for a number of reasons. Among these, there are the broad activity spectrum, the relative selectivity towards their targets (microbial membranes), the rapid mechanism of action and, above all, the low frequency in selecting resistant strains. Since biofilm resistance to antibiotics is mainly due to the slow growth rate and low metabolic activity of bacteria in such community, the use of AMPs to inhibit biofilm formation could be potentially an attractive therapeutic approach. In fact, due to the prevalent mechanism of action of AMPs, which relies on their ability to permeabilize and/or to form pores within the cytoplasmic membranes, they have a high potential to act also on slow growing or even non-growing bacteria. This review will highlight the most important findings obtained testing AMPs in in vitro and in vivo models of bacterial biofilms, pointing out the possible advantages and limits of their use against microbial biofilm-related infections.





Keywords: Actinobacillus; Antimicrobial peptides; Candida albicans; Histatin 5; Lactoferrin; Microbial Biofilms; Omiganan; Phyllomedusa; Piperacillin-tazobactam; Quorum sensing; Stenotrophomonas malthophilia; acyl ho-moserine lactone (AHLs); agglomerates; albumin; amphotericin B; antibiotic resistance; antibiotics; antimicrobial activity; arginine; benzalkonium; biofilm; cathelicidin; cecropins; central venous catheters; chronic prostatitis; cystic fibrosis; defensin-3; dental acrylic; exopolysaccharides; glucuronoxylomannan; glycosaminoglycans; haematogeneous osteomyelitis; kappacin; linezolid; lipopolysaccharide; magainins; medical device; membranolytic activity; meta-phenylene ethynylene; methicillin-resistant; methicillin-susceptible; octadecapeptide; otitis media; peptidomimetics; periodontitis; piperacillin-tazobactam; poly-glutammic acid; quorum-sensing; rifampicin; tachiplesin III; tryptophan; urinary catheters; vancomycin; vancomycin-resistant

Document Type: Research Article

DOI: https://doi.org/10.2174/092986711794088399

Publication date: 2011-01-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more